Geron to Present at the J.P. Morgan Healthcare Conference

MENLO PARK, Calif., January 8, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company, including plans for further development of its telomerase inhibitor, imetelstat, in myelofibrosis, at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled to occur at 1:30 p.m. Pacific Time on Wednesday, January 15th.

A live webcast of the presentation will be available at via the Investor Relations pages of Geron's website or at http://jpmorgan.metameetings.com/confbook/healthcare14/directlink?ticker=GERN. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.

About Geron

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACT:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com

###


HUG#1753250


distributed by